BACKGROUND: In 2018, the Centers for Disease Control and Prevention and the Vermont Department of Health investigated an outbreak of multidrug-resistant Shigella sonnei infections in a retirement community that offered a continuum of care from independent living through skilled nursing care. The investigation identified 24 culture-confirmed cases. Isolates were resistant to trimethoprim-sulfamethoxazole, ampicillin, and ceftriaxone, and had decreased susceptibility to azithromycin and ciprofloxacin. METHODS: To evaluate clinical and microbiologic response, we reviewed inpatient and outpatient medical records for treatment outcomes among the 24 patients with culture-confirmed S. sonnei infection. We defined clinical failure as diarrhea (≥3 loose stools per day) for ≥1 day after treatment finished, and microbiologic failure as a stool culture that yielded S. sonnei after treatment finished. We used broth microdilution to perform antimicrobial susceptibility testing, and whole genome sequencing to identify resistance mechanisms. RESULTS: Isolates contained macrolide resistance genes mph(A) and erm(B) and had azithromycin minimum inhibitory concentrations above the Clinical and Laboratory Standards Institute epidemiological cutoff value of ≤16 µg/mL. Among 24 patients with culture-confirmed Shigella infection, 4 were treated with azithromycin; all had clinical treatment failure and 2 also had microbiologic treatment failure. Isolates were susceptible to ciprofloxacin but contained a gyrA mutation; 2 patients failed treatment with ciprofloxacin. CONCLUSIONS: These azithromycin treatment failures demonstrate the importance of clinical breakpoints to aid clinicians in identifying alternative treatment options for resistant strains. Additionally, these treatment failures highlight a need for comprehensive susceptibility testing and systematic outcome studies, particularly given the emergence of multidrug-resistant Shigella among an expanding range of patient populations. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: In 2018, the Centers for Disease Control and Prevention and the Vermont Department of Health investigated an outbreak of multidrug-resistant Shigella sonnei infections in a retirement community that offered a continuum of care from independent living through skilled nursing care. The investigation identified 24 culture-confirmed cases. Isolates were resistant to trimethoprim-sulfamethoxazole, ampicillin, and ceftriaxone, and had decreased susceptibility to azithromycin and ciprofloxacin. METHODS: To evaluate clinical and microbiologic response, we reviewed inpatient and outpatient medical records for treatment outcomes among the 24 patients with culture-confirmed S. sonnei infection. We defined clinical failure as diarrhea (≥3 loose stools per day) for ≥1 day after treatment finished, and microbiologic failure as a stool culture that yielded S. sonnei after treatment finished. We used broth microdilution to perform antimicrobial susceptibility testing, and whole genome sequencing to identify resistance mechanisms. RESULTS: Isolates contained macrolide resistance genes mph(A) and erm(B) and had azithromycin minimum inhibitory concentrations above the Clinical and Laboratory Standards Institute epidemiological cutoff value of ≤16 µg/mL. Among 24 patients with culture-confirmed Shigella infection, 4 were treated with azithromycin; all had clinical treatment failure and 2 also had microbiologic treatment failure. Isolates were susceptible to ciprofloxacin but contained a gyrA mutation; 2 patients failed treatment with ciprofloxacin. CONCLUSIONS: These azithromycin treatment failures demonstrate the importance of clinical breakpoints to aid clinicians in identifying alternative treatment options for resistant strains. Additionally, these treatment failures highlight a need for comprehensive susceptibility testing and systematic outcome studies, particularly given the emergence of multidrug-resistant Shigella among an expanding range of patient populations. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Authors: Kate S Baker; Timothy J Dallman; Philip M Ashton; Martin Day; Gwenda Hughes; Paul D Crook; Victoria L Gilbart; Sandra Zittermann; Vanessa G Allen; Benjamin P Howden; Takehiro Tomita; Mary Valcanis; Simon R Harris; Thomas R Connor; Vitali Sintchenko; Peter Howard; Jeremy D Brown; Nicola K Petty; Malika Gouali; Duy Pham Thanh; Karen H Keddy; Anthony M Smith; Kaisar A Talukder; Shah M Faruque; Julian Parkhill; Stephen Baker; François-Xavier Weill; Claire Jenkins; Nicholas R Thomson Journal: Lancet Infect Dis Date: 2015-04-27 Impact factor: 25.071
Authors: Jennifer P Collins; Cindy R Friedman; Meseret G Birhane; Beth E Karp; Anthony Osinski; Mary W Montgomery; Deepam Thomas; Jonathan Barkley; Martha C Sanchez; Samir Hanna; Azizat A Adediran; Jessica C Chen; Hayat Caidi; Louise Francois Watkins Journal: Open Forum Infect Dis Date: 2020-04-18 Impact factor: 3.835
Authors: Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering Journal: Clin Infect Dis Date: 2017-11-29 Impact factor: 9.079
Authors: Elena Fernández Álvaro; Phat Voong Vinh; Cristina de Cozar; David R Willé; Beatriz Urones; Alvaro Cortés; Alan Price; Nhu Tran Do Hoang; Tuyen Ha Thanh; Molly McCloskey; Shareef Shaheen; Denise Dayao; Amanda Martinot; Jaime de Mercado; Pablo Castañeda; Adolfo García-Perez; Benson Singa; Patricia Pavlinac; Judd Walson; Maria Santos Martínez-Martínez; Samuel L M Arnold; Saul Tzipori; Lluis Ballell Pages; Stephen Baker Journal: Elife Date: 2022-03-15 Impact factor: 8.713
Authors: Elizabeth T Rogawski McQuade; Stephanie A Brennhofer; Sarah E Elwood; Timothy L McMurry; Joseph A Lewnard; Estomih R Mduma; Sanjaya Shrestha; Najeeha Iqbal; Pascal O Bessong; Gagandeep Kang; Margaret Kosek; Aldo A M Lima; Tahmeed Ahmed; Jie Liu; Eric R Houpt; James A Platts-Mills Journal: Proc Natl Acad Sci U S A Date: 2022-08-29 Impact factor: 12.779